Drug Trial Radar · NCT06160440
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jun 3, 2021
Primary completion
Sep 23, 2021
Study completion Feb 23, 2022
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects.Pharmacokinetic profiles in healthy subjects.Food effect in healthy subjects.Participants will complete the study including screening period, dosing period, and observation period. Researchers will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.
Conditions
- Diopathic Pulmonary Fibrosis
- Pulmonary Fibrosis
Interventions
SC1011Drug
Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events and serious adverse events related drug.Time frame: Evaluations will be conducted for up to 7 days after first administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guang Zhou University of Chinese Medicine
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.